

- [23].. Lankelma J, van der Klein E, Ramaekers F The role of 7-hydroxymethotrexate during methotrexate anti-cancer therapy. *Cancer Lett* 1980 ;9: 133–142
- [24].. Messmann R, Allegra C Antifolates. In Chabner B, Longo D, eds. 2001.Cancer Chemotherapy and Biotherapy. Philadelphia: *Lippincott Williams & Wilkins*:139–184
- [25].. Bleyer WA The clinical pharmacology of methotrexate: new applications of an old drug. *Cancer* 1978;41:36–51
- [26].. Donehower RC, Hande KR, Drake JC Chabner BA Presence of 2,4-diamino-N¹⁰-methylptericoic acid after high-dose methotrexate. *Clin Pharmacol Ther* 1979 ;26:63–72
- [27].. Balis FM Pharmacokinetic drug interactions of commonly used anticancer drugs. *Clin Pharmacokinet* 1986;11:223–235
- [28].. Abelson HT, Fosburg MT, Beardsley GP, Goorin AM, Gorka C, Link M, Link D Methotrexate-induced renal impairment: clinical studies and rescue from systemic toxicity with high-dose leucovorin and thymidine. *J Clin Oncol* 1983 ;1:208–216
- [29].. Stark AN, Jackson G, Carey PJ , Arfeen S, Proctor FJ. Severe renal toxicity due to intermediate-dose methotrexate. *Cancer Chemother Pharmacol* 1989;24:243–245
- [30].. Bleyer WA Therapeutic drug monitoring of methotrexate and other antineoplastic drugs. In: Baer DM, Dita WR, eds. *Interpretations in Therapeutic Drug Monitoring*. Chicago,: *American Society of Clinical Pathology* 1981;169–181
- [31].. Goren MP, Wright RK, Horowitz ME, Meyer WH Enhancement of methotrexate nephrotoxicity after cisplatin therapy. *Cancer* 1986;58: 2617-2621
- [32].. Goren MP, Wright RK, Horowitz ME, Crom WR, Meyer WH.Urinary N-acetyl-beta-D-glucosaminidase and serum creatinine concentrations predict impaired excretion of methotrexate *J Clin Oncol* 1987 ;5: 804-810
- [33].. Widemann BC, Balis FM, Murphy RF, Sorensen JM, Montello MJ,O'Brien M, Adamson PC Carboxypeptidase-G2, thymidine, and leucovorin rescue in cancer patients with methotrexate-induced renal dysfunction. *J Clin Oncol* 1997;15: 2125-2134
- [34]..Jariwala P, Kumar V, Kothari K,Thakkar S, and Umrigar DD Acute Methotrexate Toxicity: A Fatal Condition in Two Cases of Psoriasis. Case Reports *Dermatological Medicine*, 2014; 2014: Article ID 946716, 3 pages <http://dx.doi.org/10.1155/2014/946716>
- [35].. Widemann BC and Adamson PC. Understanding and Managing Methotrexate Nephrotoxicity.*The Oncologist* 2006; 11: 694-703
- [36]..Turra KM, Pasqualoto KF, Ferreira EI, Rando DG Molecular modeling approach to predict a binding mode for the complex methotrexate-carboxypeptidase-G2. *J Mol Model* 2012; 18:1867-1875; doi: 10.1007/s00894-011-1196-z.
- [37].. Xu M, Xu S.F.,and Yu X.C Clinical analysis of osteosarcoma patients treated with high-dose free neoadjuvant chemotherapy. *Current oncology* 2014; 21:e678-684
doi:<http://dx.doi.org/10.3747/co,21,1973>